randomized [resa]
Trial [resa]
Estrogen [horm, phsu, strd]
Plus [qlco]
Progestin [horm, phsu, strd]
Secondary Prevention [topp]
coronary heart disease [dsyn]
postmenopausal [tmco]
Women [popg]
Context [fndg]
Observational Study [resa]
coronary heart disease [dsyn]
postmenopausal [tmco]
Women [popg]
Take [hlca]
Estrogen [horm, phsu, strd]
Women [popg]
Benefit [qnco]
confirmed [qlco]
Clinical Trials [resa]
Objective [inpr]
If [qlco]
estrogen therapy [topp]
Plus [qlco]
Progestin [horm, phsu, strd]
Altered [ftcn]
coronary heart disease [dsyn]
Events [evnt]
postmenopausal [tmco]
Women [popg]
Established [qlco]
Coronary Disease [dsyn]
Design [acty]
randomized [resa]
Blinded [resa]
placebo-controlled [resa]
Secondary Prevention [topp]
Trial [resa]
setting [ftcn]
Out-patient [podg]
Community [geoa]
setting [ftcn]
Clinical Center [orgt]
participants [popg]
Women [popg]
Coronary Disease [dsyn]
Young [tmco]
postmenopausal [tmco]
Intact [qlco]
Uterus [bpoc]
Age [orga]
intervention [hlca]
mg% [qnco]
Conjugated Equine Estrogens [horm, phsu, strd]
2 5 [qnco]
mg% [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
Tablet [bodm]
Daily [tmco]
N NOS [aapp, imft]
placebo [topp]
Identical [qlco]
Appearance [orga]
N NOS [aapp, imft]
Follow-up 1 year [fndg]
Average [qnco]
Assigned [ftcn]
hormone treatment [topp]
End [spco]
End [spco]
Main [qlco]
Outcome Measures [qnco]
Primary [qlco]
occurrence [ftcn]
Myocardial Infarction [dsyn]
coronary heart disease [dsyn]
secondary [neop]
CARDIOVASCULAR [bdsy]
included [ftcn]
coronary revascularisation [topp]
Angina, Unstable [dsyn]
Congestive heart failure [dsyn]
Resuscitated Cardiac Arrest [fndg]
Stroke [dsyn]
Transient Ischemic Attack [dsyn]
peripheral arterial disease [dsyn]
Mortality [qnco]
considered [idcn]
Group [idcn]
Primary [qlco]
secondary [neop]
CARDIOVASCULAR [bdsy]
Women [popg]
Hormone [horm]
Group [idcn]
Women [popg]
placebo [topp]
Group [idcn]
Myocardial Infarction [dsyn]
coronary heart disease [dsyn]
Relative [famg]
Hazard [qlco]
lack [qlco]
Occurred [acty]
Reticular [spco]
Low density lipoprotein cholesterol level [lbpr]
High density lipoprotein cholesterol level [lbpr]
Hormone [horm]
Group [idcn]
Compared [acty]
placebo [topp]
Group [idcn]
P NOS [aapp, imft]
statistically significant [qnco]
trend [tmco]
coronary heart disease [dsyn]
Events [evnt]
Hormone [horm]
Group [idcn]
placebo [topp]
Group [idcn]
Few [qnco]
Women [popg]
Hormone [horm]
Group [idcn]
placebo [topp]
Group [idcn]
experience [menp]
Venous [bpoc]
Thromboembolic events [patf]
Relative [famg]
Hazard [qlco]
Gall Bladder Disease [dsyn]
Relative [famg]
Hazard [qlco]
Several [qnco]
End Point [qlco]
Power [hcpp]
Limited [ftcn]
Including [ftcn]
Fracture [inpo]
Mortality [qnco]
deaths [orgf]
Relative [famg]
Hazard [qlco]
Conclusions [idcn]
Average [qnco]
treatment [ftcn]
Oral [spco]
Conjugated estrogen + medroxyprogesterone [horm, phsu, strd]
Equine [mamm]
Plus [qlco]
Acetate [orch, phsu]
coronary heart disease [dsyn]
Events [evnt]
postmenopausal [tmco]
Women [popg]
Established [qlco]
Coronary Disease [dsyn]
treatment [ftcn]
Thromboembolic events [patf]
Gall Bladder Disease [dsyn]
Based [ftcn]
Finding [sosy]
CARDIOVASCULAR [bdsy]
Benefit [qnco]
Pattern [spco]
coronary heart disease [dsyn]
Events [evnt]
recommend [idcn]
Start [tmco]
treatment [ftcn]
Purpose [ftcn]
Secondary Prevention [topp]
coronary heart disease [dsyn]
GIVEN [cnce]
Favorable [qlco]
Pattern [spco]
coronary heart disease [dsyn]
Events [evnt]
Several [qnco]
therapy [ftcn]
Appropriate [qlco]
Women [popg]
Receive [qlco]
treatment [ftcn]
Continue [idcn]
